Back to Podcasts
Gradient Dissent

From Pharma to AGI Hype, and Developing AI in Finance: Martin Shkreli’s Journey

Gradient Dissent • Lukas Biewald

Tuesday, May 20, 20251h 30m
From Pharma to AGI Hype, and Developing AI in Finance: Martin Shkreli’s Journey

From Pharma to AGI Hype, and Developing AI in Finance: Martin Shkreli’s Journey

Gradient Dissent

0:001:30:19

Episode Description

In this episode of Gradient Dissent, Lukas Biewald talks with Martin Shkreli — the infamous "pharma bro" turned founder — about his path from hedge fund manager and pharma CEO to convicted felon and now software entrepreneur. Shkreli shares his side of the drug pricing controversy, reflects on his prison experience, and explains how he rebuilt his life and business after being "canceled." They dive deep into AI and drug discovery, where Shkreli delivers a strong critique of mainstream approaches. He also talks about his latest venture in finance software, building Godel Terminal “a Vim for traders", and why he thinks the AI hype cycle is just beginning. It's a wide-ranging and candid conversation with one of the most controversial figures in tech and biotech. Follow Martin Shkreli on Twitter Godel Terminal: https://godelterminal.com/ Follow Weights & Biases on Twitter https://www.linkedin.com/company/wandb   Join the Weights & Biases Discord Server: https://discord.gg/CkZKRNnaf3

Share on XShare on LinkedIn

Processing in Progress

This episode is being processed. The AI summary will be available soon. Currently transcribing audio...

Related Episodes

Comments
?

No comments yet

Be the first to comment

AI Curator

Your AI news assistant

Ask me anything about AI

I can help you understand AI news, trends, and technologies